The FDA Approval Process Needs Refinement, Not a Total Overhaul
Even though overall drug development times have not changed, questions about the clinical benefit of the drugs that have been approved through expedited pathways are being raised.
Urologic Cancers
UROLOGIC CANCER ADVISOR
FEATURED CONTENT
-
-
How Durable Are Responses to Targeted Therapies Across Single-Arm Cancer Trials?
Drugs approved based on changes to surrogate biomarker levels may be subject to measurement bias, according to investigators. -
Reporting Mechanisms for Conflict of Interest Disclosures in Medicine Need Standardization
ASCO officials examined the discrepancies in financial disclosures across platforms and call for a simplified system. -
Popular Genetic Tests Miss Many Cancer-Associated Genetic Variants, Particularly in Ethnic Minorities
The chance of missing a disease-causing variant can be as high as 100% across some groups. -
Why We Need to Change How We Look for Renal Cell Carcinoma Biomarkers
Proangiogenic or proimmunogenic genomic and transcriptomic signatures in the tumor microenvironment may have predictive value.
UROLOGIC CANCERS NEWS
Bevacizumab Adoption Tied to Use by Peers
Survey Reveals Perspective on Use of Support Garments Varies Among Patients With a Urostomy
No Link Found Between Hepatitis C Infection and Extrahepatic Cancers
Bladder Cancer Surgery Safe Following Neoadjuvant Immunotherapy
Keytruda Approved for BCG-Unresponsive, High-Risk Non-Muscle Invasive Bladder Cancer
Want to read more?
Please login or register first to view this content.
Next post in Urologic Cancers
